Sanofi (SNY) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Here we have the usual forward looking statements. We would like to remind you that information presented in this call contains forward-looking statements which are subject to substantial risk and uncertainties that may cause actual results to differ materially. We encourage you to read the disclaimer in our slide presentation. In addition, we refer you to our Form 20F on File with the U.S. SEC and our French Universal Registration Document for description of these risk factors. As usual, we'll be making comments on our performance using constant exchange rates and other non-IFRS measures. Numbers used are in millions of euros and for Q4 or full year 2025 are not stated otherwise. Please turn to slide number four. First, we have a presentation, which is a little longer due to full year results. Then we will take your questions. We aim at keeping it all to one hour, perhaps a little bit more, including questions. We appreciate other companies are also reporting today. For the Q&A, we have Olivier, Ryan, and Thomas to cover our global businesses, as well as Roy, our general counsel, and Brendan, head of manufacturing and supply. For the Q&A, you can participate in two ways, either raise your hand in Zoom or submit your question using the Q&A feature. With all of this, I'll now hand you over to Paul. Well, thank you, and hello, everyone. In 2025, we continue to develop into an R&D-driven, AI powered by a pharma company. Our strategic progress was supported by the completion of the appellate transaction, allowing us to reinvest proceeds into business development and M&A opportunities, while completing our 5 billion share buyback program. We've had a strong performance with 9.9% sales growth and new launches reached 5.7 billion euros in sales. We're pleased to have achiev...